1.3 C
New York
Tuesday, January 31, 2023

Taking On Challenges And Growing? – Arrowhead Pharmaceuticals Inc. (ARWR)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Arrowhead Pharmaceuticals Inc. (ARWR) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.53, or 1.54%, to $34.95. The Arrowhead Pharmaceuticals Inc. has recorded 148,924 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that ARWR: Encouraging Results for Phase 2 SEQUOIA Trial….

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $34.42 and fluctuated between $35.42 as its day high and $32.47 as its day low. The current market capitalization of Arrowhead Pharmaceuticals Inc. is $3.62B. A total of 1.66 million shares were traded on the day, compared to an average of 961.04K shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, ARWR has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 19,500 shares. Over the last 12 months, there were 2 BUYs and 10 SELLs from insiders. Insiders purchased 148,889 shares during that period but sold 854,385.

In the most recent transaction, Waddill William D. sold 3,200 shares of ARWR for 30.00 per share on Jan 09. After the transaction, the Director now owns 28,950 company shares. In a previous transaction on Jan 05, O’Brien Patrick sold 15,000 shares at 37.39 per share. ARWR shares that COO and General Counsel owns now total 413,375.

Among the insiders who sold shares, Hamilton James C disposed of 13,803 shares on Jan 05 at a per-share price of $37.40. This resulted in the Chief Discovery/Trans Medicine holding 191,484 shares of ARWR after the transaction. In another insider transaction, O’Brien Patrick sold 17,500 shares at $38.33 per share on Jan 03. Company shares held by the COO and General Counsel now total 363,375.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ARWR in the last 3 months, the mean price target is $65.38 with high estimates of $90.00 and low estimates of $22.00. In terms of 52-week highs and lows, ARWR has a high of $61.25 and a low of $26.81.

As of this writing, ARWR has an earnings estimate of -$0.55 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of -$0.06 per share and a lower estimate of -$0.81. The company reported an EPS of $0.41 in the last quarter, which was 612.50% higher than expectations of -$0.08.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 12 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARWR is Hold with a score of 4.60. A total of 9 analysts rated the stock as Buy while 1 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles